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http://dx.doi.org/10.1016/j.jmii.2014
1684-1182/Copyright ª 2014, TaiwanBackground: Methicillin-resistant Staphylococcus aureus (MRSA) has been increasingly causing
skin and soft tissue infections (SSTIs). Only limited studies have made comparisons between
incision and drainage (I&D) alone and I&D with adjunctive antibiotic therapy for treatment ef-
fects, and most of the studies were conducted before the emergence of MRSA. This study was
to evaluate whether antibiotics provide added benefit to I&D alone for purulent MRSA SSTIs.
Methods: This retrospective study collected data on SSTI patients, including patient demo-
graphics, treatment strategies, antibiotic susceptibilities of the infecting MRSA isolates, and
clinical outcomes over the course of 24 months.
Results: Antimicrobial drug susceptibility rate were 100% for vancomycin, teicoplanin, and
linezolid. Among the 211 patients, 7.6% were treated solely with I&D (Group A), 62.6% were
treated via I&D with adjunctive antibiotic (Group B), and 29.8% patients received only antibi-
otics (Group C). The cure rate was highest in Group A (93.8%), followed by Group B (90.9%) and
Group C (77.8%). Combining Group B and Group C, patients who were treated appropriately
demonstrated a higher cute rate (91.3% vs. 75.4%, p Z 0.005). Multivariate analysis showed
that Group B was more likely to be successfully treated compared to Group C (odds
ratio Z 2.51, 95% confidence interval Z 1.01e6.25, p Z 0.047), whereas no difference be-
tween Group A and Group B was found (odds ratio Z 2.09, 95% confidence interval Z 0.20
e22.34, p Z 0.542, data not shown).Infectious Diseases, Department of Internal Medicine, China Medical University Hospital, 2 Yu-Der
.org.tw (M.-W. Ho).
.08.030
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498 S.-H. Teh et al.Conclusion: Surgical intervention is the definitive therapy for purulent SSTIs. Adjunctive anti-
biotic therapy increased the cure rate and appropriateness of prescription is influential.
Copyright ª 2014, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Methicillin-resistant Staphylococcus aureus (MRSA) was first
documented in the 1960s. Since then, this organism has
become a major cause of serious nosocomial and
community-associated infections.1,2 Within Taiwan, MRSA
was first detected in the early 1980s, with MRSA occurrence
increasing swiftly in the 1990s.3 MRSA infections can
include sepsis, pneumonia, skin and soft tissue infections
(SSTIs), bone and joint infections, bacteremia, and
endocarditis.4,5
For SSTIs, surgical intervention is the favored therapy,
notwithstanding the fact that cure rate versus failure rate
for surgical intervention has been inconsistent in different
studies.6e8 Moreover, few studies have been carried out
specifically on comparison of incision and drainage (I&D)
alone and I&D plus antibiotic therapy, and most of the
studies were conducted before the emergence of MRSA.9e11
Adjunctive antibiotic therapy is controversial,12,13 e.g.,
Rajendran et al14 conducted a double-blind, randomized,
placebo-controlled trial and concluded that adjunctive
antibacterials do not add benefit to I&D for purulent MRSA
SSTIs whereas Ruhe et al8 conducted a retrospective,
multicenter cohort study of patients with MRSA SSTIs and
came to an opposite conclusion. Practice guidelines from
the Infectious Diseases Society of America15e17 as well as
those from the Infectious Diseases Society of Taiwan.18
recommend the use of specific antibiotics for treatment
of MRSA SSTIs; however, in practice, many doctors follow
their own prescription preferences.
In this study, we evaluated the success of surgical
intervention upon SSTIs associated with MRSA, and
compared cases that received I&D alone (Group A), I&D
with adjunctive antibiotics (Group B), and antibiotics alone
(Group C). We also evaluated whether adjunctive antibiotic
therapy was significantly helpful. Lastly, we examined the
choice of empirical antibiotic therapy in our hospital
setting. In part, our goal is to provide doctors in different
fields with feedback on their current practices so these
doctors could reevaluate and adjust their treatment habits
for consistency and moderation.Materials and methods
Patients and data collection
This study was conducted retrospectively at China Medical
University Hospital (CMUH), a 2000-bed tertiary hospital in
central Taiwan, from July 1, 2011 to June 30, 2013. Patients
were selected from various departments including out- and
inpatients.From an ethical perspective, a retrospective design
(chart review) was adopted instead of a prospective design.
For each patient, the medical record was collected for in-
formation regarding demographic data such as age, sex,
and comorbid conditions such as cardiovascular disease,
diabetes mellitus, end-stage renal disease, liver cirrhosis,
cerebrovascular disease, and malignancy. Inclusion criteria
were as follows: (1) age > 18 years; (2) detection of MRSA in
at least one patient pus culture; and (3) symptoms and signs
consistent with SSTI, i.e., presence of at least three of the
following: warmth, erythema, swelling, pain, tenderness,
lymph node swelling/tenderness, drainage/discharge, or
induration. Minor or superficial skin infections, such as
folliculitis or impetigo, as well as those with rather
complicated SSTIs (i.e., nonhealing skin ulcer or diabetic
foot infection, postsurgical wound infection, or processes
involving adjacent deep-tissue structures, including bone,
fascia, or tendon sheaths), were excluded. Pus cultures
that yielded mixed pathogens or pathogens other than
MRSA were excluded from our study. Antibiotic suscepti-
bility was recorded. Treatment data collected included
surgical/bedside interventions (i.e., I&D) performed, as
well as any additional antibiotics administered after
determination of the organism identity and susceptibility,
which result was released after 5 days of pus culture. Ul-
timately, we categorized patients’ outcomes as either (1)
cure or (2) failure, while also determining the appropri-
ateness of the prescribed antibiotics in nonsurgical and
postsurgical medical treatments. The study was approved
by the institutional review board of China Medical Univer-
sity Hospital, Taichung, Taiwan (CMUH103-REC2-077).
Definitions
Purulent SSTIs, including furuncle, carbuncle, and abscess,
are classified as severe, moderate, and mild infection.17
Severe infection was applied to those patients who have
failed incision and drainage plus oral antibiotics or those
with systemic signs of infection such as temperature >38C,
tachycardia (heart rate > 90 beats/minute), tachypnea
(respiratory rate > 24 breaths/minute) or abnormal white
blood cell count (<12  109 cells/L or <0.4  109 cells/L),
or immunocompromised patients. Moderate SSTI was
equivalent to purulent infection with systemic signs of
infection. Mild infection was defined as purulent SSTI
without signs of systemic involvement. Surgical in-
terventions indicate incision and drainage, which were
performed in the operating room or at the bedside.
Regarding the clinical outcome, treatment failure was the
primary outcome of interest and was categorized as no
clinical improvement after 48 hours, plus one or more of
the following: (1) new culture-proven MRSA SSTI while on
Figure 1. Antibiotic susceptibility of methicillin-resistant
Staphylococcus aureus. Vancomycin, teicoplanin, and line-
zolid had 100% sensitivity, followed by trimetho-
primesulfamethoxazole (TMP-SMX; 67.3%), tetracycline
(55.9%), and levofloxacin (55%). Daptomycin was not available
so it was not tested during the study period.
Management of SSTIs caused by MRSA 499antibiotics; (2) microbiological failure in which MRSA was
cultured from the original wound site after completion of
antibiotic therapy; (3) further surgical intervention; or (4)
subsequent hospitalization for the infection. Cases other-
wise were categorized as cures.
One course of antibiotic administration was tantamount
to 5 days of duration.
Appropriateness of antibiotic was defined as those pre-
scription antibiotics that were in accord with the antimi-
crobial susceptibility of the MRSA isolates; such an
antibiotic was designated as the appropriate antibiotic. The
treatment otherwise was labeled as an inappropriate
antibiotic.
Microbiology
The pus specimens were streaked on trypticase soy agar
containing 5% sheep blood (TSA II), Levine EMB agar,
Columbia CNA agar, chocolate agar, or thioglycollate broth
(Becton, Dickinson and Company, Sparks, MA, USA). The
plates were incubated at 35C for appropriate time periods.
Identification of bacteria and tests for susceptibility to
various antimicrobial agents [i.e., vancomycin, teicoplanin,
linezolid, levofloxacin, tetracycline, trimetho-
primesulfamethoxazole (TMP-SMX), clindamycin, and
erythromycin] were performed with the BD Phoenix Auto-
mated Microbiology System (Becton, Dickinson and Com-
pany). Result of antimicrobial susceptibilities of the MRSA
isolates take about 5 days to be released.
Statistical analysis
Clinical characteristics of the study patients are presented
as mean  standard deviation for continuous variable and
number and percentage (n, %) for categorical variable.
Comparison among groups was made by one-way analysis of
variance (ANOVA) for continuous variable and by Fisher’s
exact test for categorical variable. The cure rate in the
patients who were treated appropriately and inappropri-
ately with antibiotics was compared by Fisher’s exact test.
To investigate the association of clinical characteristics
with treatment outcome, univariate and multivariate lo-
gistic regression analyses were conducted. All the data
analyses were performed using SPSS version 15 (SPSS Inc.,
Chicago, IL, USA).
Results
Antimicrobial drug susceptibility rates
Antimicrobial drug susceptibility rates across all 211 pa-
tients were as follows: vancomycin, 100%, teicoplanin,
100%; linezolid, 100%, TMP-SMX, 67.3%; tetracycline, 55.9%;
levofloxacin, 55.0%; clindamycin, 19%; and erythromycin,
6.6% (Fig. 1).
Although there was no susceptibility test performed on
daptomycin for MRSA isolate during the study period, this is
considered to be an appropriate antibiotic against MRSA
SSTI due to its low minimum inhibitory concentration.
Daptomycin has been approved by the Food and DrugAdministration (FDA), USA in 2003 for the treatment of
complicated SSTIs. In various clinical trials, daptomycin
proved to be as effective as vancomycin against MRSA.19e22
Prescribed antibiotics by doctors from various
fields prior to identification of the organism and
susceptibility
We listed all the antibiotics prescribed for 195 patients (in
Group B and Group C) with MRSA by doctors in various fields
and found that the most frequently used antibiotic was
vancomycin (86 courses given). The rest were as follows:
teicoplanin (60 courses given), b-lactamase inhibitors such
as ampicillin/sulbactam and amoxicillin/clavulanic acid (36
courses given), daptomycin (32 courses given), TMP-SMX (19
courses given), quinolones such as moxifloxacin/levo-
floxacin/ciprofloxacin (16 courses given), linezolid (12
courses given), tigecycline (12 courses given), and cefra-
dine (11 courses given).
Clinical characteristics of the study patients
From July 1, 2011 to June 30, 2013, 211 patients with pu-
rulent SSTIs caused by MRSA were identified. Among all the
patients, 16 (7.6%) underwent I&D alone (Group A), 132
(62.6%) had I&D with adjunctive antibiotics treatment
(Group B), and 63 (29.8%) patients were treated merely
with antibiotics (Group C). Their age ranged from 20 years
to 94 years (mean 55.9  19 years). There were 114 (54%)
male and 97 (46%) female patients. Twenty-one (10%) pa-
tients had received antibiotics therapy before they came to
the hospital. Eighty-five (40.3%) patients were classified as
mild SSTI, 60 (28.4%) patients as moderate SSTI, and 66
(31.3%) patients as severe SSTI. Cardiovascular disease
(35.5%) was the most common underlying disease, followed
by diabetes mellitus (30.3%), and end-stage renal disease
(11.8%). The overall cure rate was 87.2% (Table 1). Table 1
lists the clinical characteristics of each study group. The
result clearly showed that the study groups differed
Table 1 Clinical characteristics of 211 patients with MRSA SSTI
Characteristics All patients Study group p
I&D alone
(Group A)
I&D plus antibiotics
(Group B)
Antibiotics alone
(Group C)
Number of patients 211 16 132 63 d
Age, y 55.9  19.0 50.2  17.7 55.4  19.4 58.3  18.3 0.282
Sex 0.290
Male 114 (54.0) 10 (62.5) 75 (56.8) 29 (46.0)
Female 97 (46.0) 6 (37.5) 57 (43.2) 34 (54.0)
Previous antibiotic therapy 0.871
No 190 (90.0) 14 (87.5) 119 (90.2) 57 (90.5)
Yes 21 (10.0) 2 (12.5) 13 (9.8) 6 (9.5)
SSTI severity <0.001
Mild 85 (40.3) 15 (93.8) 11 (8.3) 59 (93.7)
Moderate 60 (28.4) 1 (6.3) 55 (41.7) 4 (6.3)
Severe 66 (31.3) (0.0) 66 (50.0) (0.0)
Underlying condition
Cardiovascular disease 75 (35.5) 5 (31.3) 46 (34.8) 24 (38.1) 0.872
Diabetes mellitus 64 (30.3) 4 (25.0) 38 (28.8) 22 (34.9) 0.662
ESRD 25 (11.8) 4 (25.0) 16 (12.1) 5 (7.9) 0.144
Liver cirrhosis 14 (6.6) 1 (6.3) 12 (9.1) 1 (1.6) 0.117
Cerebrovascular disease 16 (7.6) (0.0) 5 (3.8) 11 (17.5) 0.004
Malignancy 16 (7.6) 2 (12.5) 7 (5.3) 7 (11.1) 0.200
Steroid using 2 (0.9) 1 (6.3) (0.0) 1 (1.6) 0.051
HIV 1 (0.5) (0.0) 1 (0.8) (0.0) > 0.99
Outcome of treatment 0.038
Failure 27 (12.8) 1 (6.3) 12 (9.1) 14 (22.2)
Cure 184 (87.2) 15 (93.8) 120 (90.9) 49 (77.8)
Data are presented as n (%) or mean  SD.
ESRD Z end-stage renal disease; HIV Z human immunodeficiency virus; I&D Z incision and drainage; MRSA Z methicillin-resistant
Staphylococcus aureus; SSTI Z skin and soft tissue infection.
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treatment outcome (p < 0.05). As to SSTI severity, a ma-
jority of the patients in Group A (93.8%) and in Group C
(93.7%) were classified as mild SSTI, whereas approximately
half of the patients in the Group B were classified as
moderate (41.7%) and severe (50%) SSTI, respectively. The
prevalence of cerebrovascular disease was apparently
higher in the antibiotics alone group (17.5%) than the two
other groups. The cure rate was substantially lower in
Group C (77.8%) when compared to that of Group A (93.8%)
and Group B (90.9%) before adjusting for other covariates.Cure rate with and without appropriate antibiotic
therapy
We reviewed the antibiotic treatment for 195 patients (in
Group B and Group C); 138 (70.8%) patients were treated
appropriately and 57 (29.2%) inappropriately. For the pa-
tients in Group B, the cure rate was significantly higher in
the appropriately treated subgroup than in the inappro-
priately treated subgroup (94.6% vs. 82.1%, p Z 0.041). In
Group C, patients who were treated appropriately showed a
higher but not significant cure rate than those were treated
inappropriately (84.4% vs. 61.1%, p Z 0.090). That was
contributed to its smaller sample size in this group (nZ 63)
hence was not statistically significant. When combining
Group B and Group C, the appropriately treated subgroupdemonstrated a higher cure rate (91.3% vs. 75.4%,
p Z 0.005) compared to its counterpart (Table 2).
Association of factors with treatment success
The result of univariate logistic analyses indicated that no
clinical characteristics were associated with treatment
outcome except for study group. Patients in Group B were
more likely to be successfully treated than those in Group C
[odds ratio (OR) Z 2.86, 95% confidence interval
(CI) Z 1.23e6.62, p Z 0.014]. By contrast, the difference
in treatment success between Group A and Group C was not
significant, despite the risk measure being even higher
(OR Z 4.29). The result of multivariate analysis remains
unchanged as patients in Group B were more likely to be
successfully treated compared to that in Group C
(OR Z 2.51, 95% CI Z 1.01e6.25, p Z 0.047). In addition,
the likelihood of successful treatment in Group A and Group
B was similar (ORZ 2.09, 95% CIZ 0.20e22.34, pZ 0.542,
data not shown). Notably, the SSTI severity was not
included in the multivariate analysis because of serious
multicollinearity involving the study group (Table 3).
Discussion
Incision and drainage has been the mainstay of therapy of
purulent SSTI since the 1950s and should be performed
Table 2 Comparison of cure rate according to appropriateness of antibiotic administration
Group/status Total Appropriate therapy Inappropriate therapy pa
I&D plus antibiotics (Group B) 0.041
Failure 12 (9.1) 5 (5.4) 7 (17.9)
Cure 120 (90.9) 88 (94.6) 32 (82.1)
Antibiotics alone (Group C) 0.090
Failure 14 (22.2) 7 (15.6) 7 (38.9)
Cure 49 (77.8) 38 (84.4) 11 (61.1)
Combined groups BþC 0.005
Failure 26 (13.3) 12 (8.7) 14 (24.6)
Cure 169 (86.7) 126 (91.3) 43 (75.4)
a Fisher’s exact test.
Data are presented as n (%).
I&D Z incision and drainage.
Management of SSTIs caused by MRSA 501whenever feasible.1,23 No study to date has evaluated the
value of I&D versus no I&D in a prospective, controlled
fashion.24 Given the widespread use of I&D and high cure
rates reported in the literature, such a trial is unlikely.
Successful drainage is considered the standard of treatment
for controlling the source of infection, thereby preventing
the development of sepsis and septic shock.25 Our study
confirms this standard, with a demonstrated cure rate of
93.8% in the I&D alone group (Group A) and 90.9% in the I&D
with adjunctive antibiotic group (Group B), values consis-
tent with a number of previous studies.6e8 However, the
role of ancillary antibiotics is disputable. There are multi-
ple trials evaluating adjunctive antibiotics for drained skin
abscess, with different outcomes.8,12e14,26e28
In the present study, we found that the adjunctive use of
antibiotics provided a key component of successfulTable 3 Factors associated with treatment success
Univariate analysi
Predictor OR 95% CI
Age, per y 0.99 0.97e1.02
Male/female 1.55 0.69e3.51
Previous antibiotic therapy 1.44 0.32e6.56
SSTI severitya
Mild 1 Reference
Severe 2.20 0.74e6.53
Moderate 1.02 0.41e2.57
Cardiovascular disease 1.36 0.56e3.28
Diabetes mellitus 0.59 0.26e1.35
ESRD 0.74 0.23e2.35
Liver cirrhosis NA NA
Cerebrovascular disease 1.03 0.22e4.80
Malignancy 0.61 0.16e2.29
Steroid using 0.14 0.01e2.34
HIV NA NA
Study group
I&D alone 4.29 0.52e35.33
I&D þ antibiotics 2.86 1.23e6.62
Antibiotics alone 1 Reference
a SSTI severity was not included in the multivariate model due to a
CI Z confidence interval; ESRD Z end-stage renal disease; HIV Z
NA Z not applicable; OR Z odds ratio; SSTI Z skin and soft tissue intherapy, especially when an appropriate antibiotic was
used. Hence, rectification of antibiotic administration is of
paramount importance.
In fact, we detected that, for the patients in Group B,
the cure rate was significantly higher in the appropriately
treated subgroup than in the inappropriately treated sub-
group (94.6% vs. 82.1%, p Z 0.041). Due to the smaller
sample size (n Z 63) in Group C, the corresponding com-
parison turned out as statistically insignificant (84.4% vs.
61.1%, p Z 0.090); however, when combining Group B and
Group C, we found that the appropriately treated subgroup
demonstrated a higher cute rate (91.3% vs. 75.4%,
p Z 0.005) compared to its counterpart.
Among our MRSA isolates, 100% were susceptible to
vancomycin, teicoplanin, and linezolid, with susceptibilitys Multivariate analysis
p OR 95% CI p
0.605 1.00 0.97e1.02 0.883
0.287 1.33 0.54e3.29 0.534
0.638 1.36 0.28e6.58 0.698
d
0.154
0.961
0.493 2.92 0.87e9.82 0.084
0.211 0.32 0.10e1.04 0.059
0.611 0.88 0.22e3.55 0.860
NA NA NA NA
0.971 1.49 0.23e9.72 0.674
0.462 0.54 0.12e2.40 0.418
0.172 0.15 0.01e3.94 0.254
NA NA NA NA
0.176 5.25 0.49e55.69 0.169
0.014 2.51 1.01e6.25 0.047
d 1 Reference d
pparent multicollinearity involving study group.
human immunodeficiency virus; I&D Z incision and drainage;
fection.
502 S.-H. Teh et al.also observed for TMP-SMX, tetracycline, and levofloxacin
(in 67.3%, 55.9%, and 55% of isolates, respectively).
While there are existing guidelines to be followed in
tackling MRSA related SSTIs, we found that many doctors in
various fields in our hospital instead selected antibiotics
according to their own taste or past experience. Practice
guidelines for the diagnosis and management of skin and
soft tissue infections: 2014 update by the Infectious Dis-
eases Society of America17 has clearly suggested that, for
mild purulent SSTI, I&D alone is indicated; for moderate
purulent SSTI, it should be treated with I&D plus TMP-SMX
or doxycycline as empiric antimicrobial therapy but
remain or switch to TMP-SMX if MRSA is isolated. As for
severe purulent SSTI, in addition to I&D, either vancomycin
or daptomycin or linezolid or televancin or ceftaroline is
recommended as empiric antimicrobial therapy and should
remain unchanged when MRSA is suspected or confirmed.
This guideline also stresses that clindamycin may be used if
clindamycin resistance is <10e15% at the institution. In our
study, b-lactam agents such as amoxicillin/clavulanic acid,
ampicillin/sulbactam, and cefradine were actually being
frequently prescribed. We attribute the inappropriate use
of antibiotics to the lack of awareness that empiric treat-
ment with b-lactam agents may no longer be appropriate to
be prescribed in Taiwan, an area with a high prevalence of
MRSA infection.3,29
To address the challenges noted in our study, further
information regarding MRSA should be well disseminated
among our doctors, possibly including the use of a local
algorithm regarding treatment of SSTIs.
There are several limitations in the present study. First,
this study was limited by its small sample size, so may not
be an accurate representation of a wider population. Sec-
ond, the study was limited to patients from whom a culture
yielded MRSA; however, some milder SSTIs, from which
culture samples were not obtained, but that might none-
theless have involved MRSA, would have been excluded
from our study. Third, we were not able to assess antibiotic
compliance of each patient, nor whether they had been
receiving other treatments (such as hyperbaric oxygen
therapy) outside of the hospital. Fourth, we may not have
been informed about cases that included spontaneous
drainage of abscesses. Fifth, we did not include body mass
index as an assessment factor (due to the paucity of
charting, especially in outpatient department and emer-
gency room patients); obesity might have affected the
pharmacokinetic profiles of antimicrobial drugs.30 Sixth,
cases might have been underestimated in terms of their
underlying conditions, because related tests (such as oral
glucose tolerance test to determine diabetic status) were
not performed on all the participants. Seventh, we did not
differentiate community-associated MRSA from hospital-
associated MRSA due to lack of relevant facilities, and
thereby could not offer a detailed analysis on this aspect.
Eighth, I&D techniques were not standardized among the
treating doctors. Differences in I&D techniques may have
influenced SSTI outcomes. Ninth, there is to date no
commonly agreed classification of the clinical presentation
of SSTI, or a score for assessing the clinical severity of an
SSTI validated by either prospective or retrospective clin-
ical studies; despite several severity classification rules for
SSTIs being proposed,15e17,31 the best classification rule isyet unknown.32 Our classification here may not be consis-
tent with other studies/guidelines, and thereby may have
affected treatment outcomes.
In conclusion, surgical intervention, especially I&D, re-
mains the cornerstone of therapy for purulent SSTIs.
Adjunctive antibiotic use is determinative if an appropriate
antimicrobial is being used. Our results suggest that van-
comycin, teicoplanin, and linezolid (antibiotics to which
100% of our isolates were susceptible) are still the drug of
choice in terms of antibiotic selection in our hospital
setting; TMP-SMX, tetracycline, and levofloxacin (antibi-
otics to which 67.3%, 55.9%, and 55% of our isolates were
susceptible, respectively) might be the next consideration.
The establishment of a local use treatment algorithm to
deal with SSTIs might be of help for doctors, because
avoiding the prescription of inappropriate antibiotics would
help to prevent the generation of resistant pathogens in
this era of MRSA.
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